Now FDA Approved
- Treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency
- Control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor (vWF) are not available
- Second-line therapy for von Willebrand disease (vWD)
- Control of uremic bleeding after other treatment modalities have failed
Limitations of Use: Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used for replacement of factor VIII.
Have questions or want to order Pathogen Reduced Cryoprecipitated Fibrinogen Complex?
Connect with us and your Cerus Regional Business Director will follow up with you directly.